IL316663A - Salt and crystal forms of epidermal growth factor receptor inhibitor - Google Patents
Salt and crystal forms of epidermal growth factor receptor inhibitorInfo
- Publication number
- IL316663A IL316663A IL316663A IL31666324A IL316663A IL 316663 A IL316663 A IL 316663A IL 316663 A IL316663 A IL 316663A IL 31666324 A IL31666324 A IL 31666324A IL 316663 A IL316663 A IL 316663A
- Authority
- IL
- Israel
- Prior art keywords
- salt
- growth factor
- factor receptor
- epidermal growth
- crystal forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
- C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338371P | 2022-05-04 | 2022-05-04 | |
| PCT/US2023/020925 WO2023215431A1 (en) | 2022-05-04 | 2023-05-04 | Salt and crystal forms of an epidermal growth factor receptor inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316663A true IL316663A (en) | 2024-12-01 |
Family
ID=86688767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316663A IL316663A (en) | 2022-05-04 | 2023-05-04 | Salt and crystal forms of epidermal growth factor receptor inhibitor |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250282761A1 (enExample) |
| EP (1) | EP4519254A1 (enExample) |
| JP (1) | JP2025517634A (enExample) |
| KR (1) | KR20250012078A (enExample) |
| CN (1) | CN119923392A (enExample) |
| AU (1) | AU2023265064A1 (enExample) |
| CA (1) | CA3251624A1 (enExample) |
| IL (1) | IL316663A (enExample) |
| MX (1) | MX2024013485A (enExample) |
| TW (1) | TW202409016A (enExample) |
| UY (1) | UY40256A (enExample) |
| WO (1) | WO2023215431A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024097270A1 (en) * | 2022-11-01 | 2024-05-10 | Blueprint Medicines Corporation | Egfr inhibitors for treatment of cancer |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113493419A (zh) * | 2020-03-18 | 2021-10-12 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| CN113493420B (zh) * | 2020-03-18 | 2025-04-25 | 南京迈晟科技有限责任公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| IL302457A (en) * | 2020-10-30 | 2023-06-01 | Blueprint Medicines Corp | Pyrimidine compounds, preparations and their medical applications |
| CA3196857A1 (en) * | 2020-10-30 | 2022-05-05 | Gurulingappa Hallur | Pyrimidine compounds, compositions, and medicinal applications thereof |
-
2023
- 2023-05-04 EP EP23728478.1A patent/EP4519254A1/en active Pending
- 2023-05-04 US US18/862,859 patent/US20250282761A1/en active Pending
- 2023-05-04 CN CN202380051632.8A patent/CN119923392A/zh active Pending
- 2023-05-04 IL IL316663A patent/IL316663A/en unknown
- 2023-05-04 TW TW112116649A patent/TW202409016A/zh unknown
- 2023-05-04 UY UY0001040256A patent/UY40256A/es not_active Application Discontinuation
- 2023-05-04 AU AU2023265064A patent/AU2023265064A1/en active Pending
- 2023-05-04 WO PCT/US2023/020925 patent/WO2023215431A1/en not_active Ceased
- 2023-05-04 KR KR1020247040290A patent/KR20250012078A/ko active Pending
- 2023-05-04 CA CA3251624A patent/CA3251624A1/en active Pending
- 2023-05-04 JP JP2024564833A patent/JP2025517634A/ja active Pending
-
2024
- 2024-10-31 MX MX2024013485A patent/MX2024013485A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202409016A (zh) | 2024-03-01 |
| AU2023265064A1 (en) | 2024-11-14 |
| US20250282761A1 (en) | 2025-09-11 |
| MX2024013485A (es) | 2024-12-06 |
| WO2023215431A1 (en) | 2023-11-09 |
| EP4519254A1 (en) | 2025-03-12 |
| JP2025517634A (ja) | 2025-06-10 |
| CN119923392A (zh) | 2025-05-02 |
| KR20250012078A (ko) | 2025-01-23 |
| CA3251624A1 (en) | 2023-11-09 |
| UY40256A (es) | 2023-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL309469A (en) | Salt and crystal forms of epidermal growth factor receptor inhibitor | |
| IL297625B2 (en) | PI3K-alpha inhibitors and methods of using them | |
| IL317847A (en) | Salts of SOS1 inhibitors | |
| SG11202109438TA (en) | A salt and crystal form of a fak inhibitor | |
| IL312348A (en) | HIF-2ALPHA inhibitors and methods of using it | |
| IL321357A (en) | KIF18A inhibitors and their uses | |
| IL319748A (en) | PCSK9 inhibitors and methods of using them | |
| EP4222151A4 (en) | PROTEIN ALPHA KINASE 1 INHIBITORS AND METHODS OF USE | |
| EP4244231A4 (en) | CRYSTALLINE SOLID MEGLUMIN SALT INHIBITOR OF BCL AND METHOD OF PREPARING AND USING THE SAME | |
| EP3969442A4 (en) | FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS | |
| IL318393A (en) | Azaquinazoline compounds and methods of use | |
| EP4329735A4 (en) | KCNT1 INHIBITORS AND METHODS OF USE | |
| IL309447A (en) | Pharmaceutical preparations of epidermal growth factor receptor inhibitor | |
| EP4329766A4 (en) | RIPK1 INHIBITORS AND METHODS OF USE | |
| EP4148055A4 (en) | CRYSTAL FORM OF A MACROCYCLIC TYROSINE KINASE INHIBITOR AND PROCESS FOR PRODUCTION THEREOF | |
| HK40124180A (en) | Salt and crystal forms of an epidermal growth factor receptor inhibitor | |
| CA3280370A1 (en) | Crystal form and use of parp7 inhibitor and salt thereof | |
| EP4438606A4 (en) | NEW CRYSTALLINE FORM OF A NUCLEOSIDE COMPOUND AND ITS SALT | |
| EP4161488A4 (en) | RHO-KINASE INHIBITOR RELEASING IMPLANTS AND RELATED METHODS OF USE | |
| CA3278084A1 (en) | Crystal form of alk inhibitor or salt and solvate thereof, preparation method therefor, and use thereof | |
| CA3298336A1 (en) | Salt of thiazolopyrazine compound or crystal thereof and use thereof | |
| HK40130329A (en) | Salt form and crystal form of plk1 kinase inhibitor, and preparation method therefor and use thereof | |
| CA3271284A1 (en) | Salt and crystal form of heterocyclic derivative inhibitor, and preparation method therefor and use thereof | |
| HK40126598A (en) | Salt and crystal form of heterocyclic derivative inhibitor, and preparation method thereof and use thereof | |
| IL317043A (en) | RIPK1 inhibitors and methods of use |